CureVac Stock Soars on BioNTech Buyout

The shares are breaking out of penny stock territory to hit 52-week highs

Laura McCandless

Deputy Editor

Jun 12, 2025 at 11:08 AM

BNTX
CVAC

Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that BioNTech (BNTX) is acquiring the company in all-stock deal worth $1.25 billion. The merger is still awaiting review from the German Economy Ministry.

Today's pop has CVAC trading at 52-week highs, conquering resistance at the $5 level, which kept it in penny stock territory for the last year. Since the start of 2025, the equity is up 63.5%.

CureVac stock's typically quiet options pits are booming today. The stock has already seen 45 times the average daily options volume, with the most activity at the June 6 call, where new positions are being opened.

Short interest has been unwinding, down 14.1% in the last two weeks, but the amount sold short still accounts for 4.4% of the stock's available float. It would take shorts over six days to cover, at CVAC's average pace of trading.

Follow @Schaeffers

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.